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Abstract (200 words): 
Purpose of review: 
This review explores the clinical and pathological features of Fabry disease with particular focus on 
the cardiac pathology and presentation and the differences between the classical and later onset 
cardiac predominant forms. New modalities of imaging, biomarkers and long term treatment effects 
are discussed. 
Recent findings: 
Fabry disease is clinically heterogeneous and in women the clinical severity has recently been linked 
to skewing of X-inactivation. Two phenotypes have been described; one with early onset 
manifestation including pain and one with later onset single organ manifestations; however, the 
cardiac outcomes in these two groups appears similar. Fibrosis is found in renal and cardiac tissues on 
biopsy and appears to be a critical point in the pathology of Fabry disease after which response to 
enzyme replacement therapy is more limited. In vitro studies have suggested that lyso- 
globotriosylceramide may have an important role in the generation of fibrosis. Imaging including 
cardiac magnetic resonance imaging may have a role in detection of early stages of the disease. Long 
term outcomes for patients treated with enzyme replacement therapy are now being described with 
positive effects on renal function, cardiac architecture and clinical events with some suggestion that 
patients treated at earlier points in the disease course may have better outcomes. 
Summary: 
Fabry disease is a heterogeneous condition. Recent advance in understanding pathology, disease 
processes and treatment effects may enable future rational targeting of treatment to early disease 
with improved outcomes. 
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Abbreviations: 
Enzyme replacement therapy: ERT 
Globotriaosylceramide: Gb3 
alpha galactosidase A: GLA 
Left Ventricular hypertrophy: LVH 
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Glomerular Filtration Rate: GFR 
Mainz severity score index: MSSI 
Chronic Kidney Disease: CKD 
New York Heart Association: NYHA 
Cardiac magnetic resonance imaging: CMR 
Electrocardiogram: ECG 
 
 
Introduction 
Fabry disease (MIM 301500) is a rare X-linked lysosomal storage disorder resulting from deficiency of 
Alpha Galactosidase A and accumulation of it substrate globotriaosylceramide (Gb3) (1). Clinical 
features include pain in the extremities (acroparasthesia), sweating abnormalities, a rash 
(angiokeratoma) and gastrointestinal symptoms. Progression to proteinuric renal failure, cardiac 
hypertrophy and stroke may occur (2). The presentation is very heterogeneous affecting both males 
and females of all ages. Broadly, two phenotypes have been recognized an early onset classical form 
manifesting in childhood and a later onset form which often affects a single organ without the 
peripheral manifestations. However, the relationship of individual mutations to clinical presentation 
is not always clear and the impact of other factors on progression is unknown. Treatment is by 
intravenous infusion of the missing enzyme, (enzyme replacement therapy, ERT) and whilst originally 
described in terms of effects on surrogates such as substrate clearance on biopsy (3,4,) it has now 
been available for over 15 years and the long term clinical effects are emerging and new modalities of 
therapy are being described. 
 
Pathophysiology 
Over 600 mutations encompassing the 7 exons of the alpha galactosidase A (GLA) gene have been 
described with varying effects on alpha galactosidase A enzyme activity depending on type and site of 
mutation (5). In addition a specific splice-site mutation (IVS4+919>A) has been found to be prevalent 
within the Chinese Han population (6). While the relationship between GLA mutation, reduction in 
enzyme activity and substrate accumulation is qualitatively clear the role of individual mutations in 
generation of quantitatively different levels of substrate and its derivatives in tissues and their impact 
on organ changes is not well understood. The accumulated sphingolipid substrate Gb3 is converted to 
lysos Gb3 by acid ceramidase within tissues and is detectable on biopsy of affected organs, in the 
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circulation and in the urine (7,8). Findings in an in vitro model of increased collagen production after 
addition of lyso Gb3 point to a critical role in the genesis of fibrosis found in heart and kidney, possibly 
through notch1 signalling (9). However, little lyso-Gb3 is found in the plasma of patients with some so 
called late onset mutations associated with relatively preserved enzyme activity despite significant 
single organ effects such as left ventricular hypertrophy, posterior wall fibrosis, conduction defects 
and ensuing morbidity (10). 
 
Diagnosis 
Diagnosis in males is by confirmation of reduced alpha galactosidase A enzyme activity with 
confirmatory genotyping (11). However, in females random X-inactivation in the peripheral blood may 
result in non-informative enzyme activity in the normal range and a requirement for genotyping of 
the GLA gene to confirm the diagnosis. Measurement of Gb3 substrate and its derivatives such as lyso 
Gb3 and within organs, plasma and urine may be helpful in classification and assignment of 
pathogenicity but are not independently discriminatory for diagnosis since elevated levels have been 
found in patients with cardiac symptoms but without Fabry disease suggesting a possible contributory 
role to other conditions (12). Screening studies of patients with relatively non-specific symptoms may 
result in the detection of variants of unknown significance for which the pathogenic impact is unclear 
(13). Recent consensus initiatives have attempted to define criteria for the diagnosis of Fabry disease 
when the pathogenicity of a new mutation has not previously been described. Critical attributes 
include demonstration of low enzyme activity, relevant clinical features and ultimately demonstration 
of substrate accumulation in the relevant organ by biopsy where possible (14). Whilst classical and 
later onset forms of the condition often segregate with specific genotypes this is not absolute and 
each case should be individually assessed. For example while the N215S GLA mutation has been 
denoted a ‘cardiac variant’ presenting with cardiomyopathy, some patients have been described with 
proteinuria and renal failure (15).  
Prior to diagnostic testing patients require genetic counselling and information in regard to possible 
future prognosis, therapy and implications of the condition for family making, employment and 
insurance. Pedigree analysis of an X-linked condition will be informative of genetically at risk 
individuals and individuals may require support in communicating the possibility of a life-limiting 
diagnosis to other family members (16). However, genetic screening of younger family members 
provides an opportunity for early diagnosis assessment and therapy of individuals who might have 
otherwise only come to medical attention after a detrimental event.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 Screening and prevalence 
In early studies the prevalence of Fabry disease was reported to be 1 in 117 000 (Australia)(17), 1 in 
468 000 (Netherlands) (18) and 1 in 833 000 (Portugal) (19); however new born screening has detected 
a higher incidence of GLA mutations for example 1 in 3100 newborn Italian males (20) and 1 in 1600 
in Taiwan (21). The pathogenicity and natural history of all of all mutations found in newborns is 
unknown and there remain some ethical implications of such strategies. Screening in Taiwan has 
uncovered a large population of patients with a single GLA mutation resulting in a later onset cardiac 
predominant phenotype of Fabry disease with more immediate clinical relevance to parents and 
grandparents than the newborn index case (22). The screening of targeted high risk populations has 
informed prevalence in symptomatically enriched populations; a systematic review by Linthorst et al. 
of screening studies in high risk groups showed a prevalence of 0.33% in male dialysis patients, 0.1% 
in female dialysis patients and at least 1% for patients with left ventricular hypertrophy (23). However, 
the prevalence in such screening studies may be artificially inflated due to removal of patients with 
other diagnoses and possible misattribution of pathogenicity to polymorphisms. 
 
Clinical Features and classification 
In the classical early onset form of the condition, males with low enzyme activity present during 
childhood with pain, gastrointestinal symptoms and sweating abnormalities (24).  Intolerance to heat 
and exertion provokes painful episodes in the extremities and leads to a failure to participate in a 
sporting activities and pain crises at the time of febrile illnesses may prolong absence from school. 
Corneal opacities (cornea verticillata) and rash (angiokeratoma) in characteristic regions around the 
mouth, umbilicus, scrotum and hands are external features of the disease which may suggest the 
diagnosis (25).  Proteinuria occurs in the second decade heralding decline in glomerular filtration rate 
and progression to end stage renal disease in a proportion of patients whilst concentric left ventricular 
hypertrophy and conduction abnormalities emerge subsequently. In addition to pain, neurological 
manifestations include hearing loss, CNS white matter lesions of unknown pathogenesis, TIA and 
stroke (26).  Despite the X-linked inheritance females may manifest any of the clinical features of Fabry 
disease and whilst often of later onset and milder severity compared with males, significant clinical 
events including renal failure, arrhythmias and stroke are described. This finding emphasizes the 
importance of local enzyme activity and substrate accumulation in the tissues compared with other 
X-linked disorders such as haemophilia where a small percentage of normal enzyme activity may 
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function effectively within the circulation. The particularly variable severity in females is probably 
related to the random nature of X-inactivation with recent studies demonstrating a relationship 
between clinical features, enzyme activity and X-inactivation in the peripheral blood (27). Further 
work is required to confirm the relevance of X-inactivation in cardiac and renal tissues on local organ 
manifestations.  
More recently case finding studies aimed at patients with single organ manifestations such as renal 
failure, left ventricular hypertrophy and stroke have facilitated the diagnosis of patients with 
apparently later onset manifestations and more preserved enzyme activity (non-classical disease). 
Whilst diagnosis is later due to the absence of childhood suggestive symptoms such as 
acroparasthaesia and angiokeratoma, organ manifestations may be comparable to the classical form 
with similar burden of organ-specific morbidity.  
 
Cardiac features 
Features of the cardiac involvement of Fabry disease include left ventricular hypertrophy, rarely with 
left ventricular outflow tract obstruction, impaired myocardial function, and progressive myocardial 
fibrosis, resulting in chest pain, heart failure and arrhythmias, including, on occasion, sudden cardiac 
death (28). Perinuclear vacuolation, intracytoplasmic whorled bodies, myocyte hypertrophy and 
fibrosis have been described on cardiac biopsy and at post mortem with macroscopic findings of left 
ventricular hypertrophy, posterior wall thinning and mild right ventricular hypertrophy. Coronary 
arteries are thickened without occlusion of the lumen with little atherosclerotic disease and whilst 
valvular abnormalities have been described they are rarely clinically significant (29).   
ECG abnormalities, such as shortened PR interval, LVH on voltage criteria, and t wave inversion are 
also early findings and may precede detection of LVH on echocardiography. Pacing for atrioventricular 
and sinus node disease is common; QRS duration and PR interval were found to be independent 
predictors of future anti-bradycardia pacing (30). 
Risk factors most strongly associated with CV events of myocardial infarction, heart failure and death 
in both sexes were found to be hypertension and LVH (31). Patients with renal involvement have been 
found to have more severe cardiac disease. Class 5 chronic kidney disease (CKD5) was associated with 
worse baseline cardiac parameters and progressive LVH.  LVMI increased by 35.4±31.8 g/m2.7 in CKD5 
vs 5.7±7.9 g/m2.7 in non-CKD5, p=0.044) and cardiovascular events (including sudden death, 
arrhythmia and pacing device insertion) occurred in 100% of patients with CKD5 (21 events) compared 
with 26% in non-CKD5 patients (7 events) (32). However, the type of mutation does not appear to be 
associated with cardiac outcome. In a study of 207 consecutive patients from one cardiology clinic 
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(47% male, mean age 44 years) 28% had mutations associated with a cardiac predominant phenotype, 
10% developed severe heart failure (NYHA) ≥3)  6% developed atrial fibrillation, 6% received device 
for bradycardia,  and 3% cardiac deaths were recorded. When a composite endpoint of new onset AF, 
NYHA ≥ 3, device insertion for bradycardia and cardiac death was considered the incidence: 2.64 per 
100 person-years (CI 1.78 to 3.77) did not differ between significantly between classical and cardiac 
variant late onset phenotypes (33). Independent predictors of outcome were the Mainz severity score 
index (MSSI) and QRS interval but not genotype. (33). 
 
Myocardial fibrosis: cardiac imaging and biomarkers 
Myocardial fibrosis, a common finding within the posterior wall at post mortem appears to correspond 
with posterior wall late gadolinium enhancement on cardiac magnetic resonance (CMR) imaging (34). 
Subjects with high annual increase in left ventricular fibrosis are at risk for sudden cardiac death. In 
males, fibrosis is generally detected subsequent to emergence of LVH. One study found late 
enhancement was not seen with end-diastolic LV wall thickness less than 12 mm (LV mass <99 g/m2) 
and was always associated with low systolic strain rate however in females fibrosis was described prior 
to LVH and the severity of functional impairment was independent of LV wall thickness (35). This 
finding has possible implications for the timing of initiation of specific therapy since late gadolinium 
enhancement was associated with increased LV Mass, worse myocardial function and failure of 
regression with enzyme replacement therapy (36). Similarly, abnormalities on 2D speckle-tracking 
have been independent of LVH and in patients with normal ejection fraction. Morris et al. found 
principal factors linked to reduced myocardial function include LV septal wall thickness > 15 mm, RV 
free wall thickness > 7 mm, and LV longitudinal dysfunction.  LV and RV fibrosis were also linked to 
reduced LV and RV strain and patients with reduced LV, RV, and LA strain had a worse functional class 
(37).  
A recent sophistication of Fabry CMR imaging is non-contrast T-1 mapping where lipid is known to 
reduce the T1 parameter and was hypothesized to detect early cardiac involvement. T1 in Fabry 
disease appears to be discriminatory of other disorders causing LVH such as hypertension, 
hypertrophic cardiomyopathy and amyloid, and also to correlate inversely with left wall thickness. 
Low T1 may represent sphingolipid infiltration and ‘pseudonormalisation’ in the posterior, wall 
fibrosis, however correlative biopsy data is not yet available (38). Low T1 appears to occur in some 
patients before hypertrophy and may be a marker of early involvement and possible imaging marker 
of treatment effect.  
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Potential circulating biomarkers include both substrate and related compounds and downstream 
markers of pathophysiology including fibrosis. Reports are varied as to the effects of lyso-Gb3 on 
collagen synthesis (9,39). However, matrix metalloproteinase 9 was significantly higher in Fabry 
disease and correlated positively with MSSI and negatively with endocardial fraction shortening (40). 
NT propBNP is a marker of diastolic dysfunction and correlated with age, creatinine, left atrial index, 
and abnormal ECG (41). 
 
Fabry specific therapy 
Current specific therapy for Fabry disease entails intravenous infusion of recombinant (agalsidase 
beta; Fabrazyme) or gene-activated (agalsidase alfa; Replagal) preparations of the deficient alpha 
galactosidase A. Both preparations have been available for 15 years and whilst initial demonstration 
of effect was based on substrate clearance on biopsy, reduction in pain and left ventricular 
hypertrophy (3,4) longer term clinical endpoints in patients starting early and later in the course of 
the disease are now being reported. A recent study of severe clinical events, renal function and cardiac 
structure in patients from original phase 3 clinical trials who had received agalsidase beta for ten years 
found 81% were free of severe clinical events (chronic dialysis, kidney transplant, myocardial 
infarction, congestive heart failure, major cardiac procedures, stroke and death) at ten years and 
survival was 94% (42). Patients classified at the outset as having low or high renal involvement had 
different slopes in GFR (-1.89 vs -6.82 mL/min/1.73m2/year). Similarly patients who started treatment 
later (over 40 years) had increases in IVST LPWT compared with those under the age of 40 who had 
no change in LPWT and under 30 who had no change in IVST; patients commencing therapy  ≥30 years 
to <40 years had small increases in IVST. Further suggestion of the importance of early therapy is 
provided in a retrospective registry study of patients receiving agalsidase beta for 5 years where the 
risk of severe renal, cardiovascular and cerebrovascular clinical events during the first six months of 
therapy was greater in males, and patients > 40 years and in each case decreased with further time 
receiving enzyme replacement (43). In patients with clinical events prior to therapy the risk of further 
events during the first 6 months was not different to patient without events but did increase 
thereafter. 
A single centre retrospective study of patients receiving agalsidase alfa for ten years found heart 
failure classification had improved by at least 1 class in 22/42 patients, and angina was stable or 
improved in 41/42 patients. During this time no patient without LVH at baseline developed new LVH 
patients. In males with baseline values ≥50 g/m2.7, LVMI was significantly reduced after 10 years 
although in similar females whilst an early improvement was noted mean LVMI was not significantly 
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different from baseline at ten years (44). In an attempt to compare long term registry data of ERT 
treated patients with the natural history of untreated patients data of patients from the Fabry 
Outcome Survey (a Shire sponsored database) who were had received agalsidase alfa for a median of 
5 years were compared with published series of untreated patients. A slower decline in renal function 
and slower progression of LVH was seen in patients receiving agalsidase alfa was noted and clinical 
events occurred later in treated patients, (16% risk of a composite morbidity event after 24 months 
with ERT vs 45% without treatment). (45) 
  
Emerging therapies 
Recently the utility of active site specific chaperone therapy that bind and stabilise mutant protein 
facilitating trafficking to the lysosome has been explored. Results of three phase 2 studies of 
migalastat HCL (AT-1001, GR181413A, 1-deoxygalactonojirimycin), an orally bioavailable imino sugar,  
have been presented indicating increased activity of alpha galactosidase A and reduction of substrate 
in relevant tissues in vivo. (46,47) Phase 3 studies are ongoing. The use of substrate reduction therapy 
by inhibition of glucosyl ceramide synthase is an alternative approach to the development of an oral 
therapy for Fabry disease that is in early clinical development. Treating Fabry mice with compound 
Genz-682452 resulted in reduced tissue substrate and a delayed the onset of a deficit in 
thermosensory responses. The effects were most notable in young mice prior to the development of 
pathology (48). These products are not yet approved and remain investigational. 
 
Conclusion 
After 15 years of the availability of ERT for Fabry disease long term data for the follow up of original 
trial cohorts and registry studies is demonstrating an effect not only on symptoms and surrogates 
including left ventricular mass and GFR but also on clinical events and mortality. Risk analyses indicates 
that patients commencing therapy at older ages and later stages of disease are less likely to have good 
response to therapy. This new understanding may allow the coherent use of investigations to detect 
early disease and direct Fabry-specific therapy to the pre-fibrotic stage of disease when outcomes 
might be optimised. 
 
Key points: 
 Fabry disease is a rare X-linked disorder resulting in renal dysfunction, left ventricular 
hypertrophy and stroke.  
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 An early onset classical form is characterised by acroparasthaesia, angiokeratoma, sweating 
abnormalities and corneal whorls; a later onset form with single organ, usually cardiac 
manifestations is recognised. 
 The pathology of cardiac and renal dysfunction appears to involve fibrosis and having 
occurred this appears to limit the effects of Fabry specific enzyme replacement therapy 
 New imaging biomarkers such as t1 mapping may allow the detection of early stages of the 
disease 
 Long term data on patients treated with Enzyme replacement therapy are now becoming 
available and point to better responses when patients are treated at an earlier stage 
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